Overview

GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles

Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
0
Participant gender:
Female
Summary
Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Treatments:
Triptorelin Pamoate
Criteria
Inclusion Criteria:

- Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with
pituitary downregulation by GnRH antagonist.

Exclusion Criteria:

- Moderate or severe endometriosis.

- Hydrosalpinx.

- Uterine abnormalities.

- Myoma.

- Previous uterine surgery.